Sun Pharma posts consolidated net income of Rs 1,984 crore in This autumn

Sun Pharmaceutical Industries on Friday acknowledged its consolidated net income stood at Rs 1,984 crore for the fourth quarter ended March 31, 2023, aided by sturdy product sales all through markets.

The Mumbai-based agency had reported an online lack of Rs 2,277 crore throughout the January-March quarter of ultimate yr.

Excluding the distinctive objects, adjusted net income for the fourth quarter closing fiscal stood at Rs 2,156 crore, up 36 per cent, over the fourth quarter of 2021-22 fiscal, Sun Pharma acknowledged in a regulatory submitting.

Total revenue from operations rose to Rs 10,931 crore for the March quarter as in distinction with Rs 9,447 crore throughout the year-ago interval.

For the yr ended March 31, 2023, the drug essential reported an online income of Rs 8,474 crore as in opposition to Rs 3,273 crore in FY22.

Excluding the distinctive objects, adjusted net income for FY23 stood at Rs 8,645 crore, up 13 per cent over 2021-22 fiscal. Total revenue from operations elevated to Rs 43,886 crore as in opposition to Rs 38,654 crore in FY22.

The agency’s board has useful a closing dividend of Rs 4 per share for the financial yr 2022-23.

“Several of our businesses, including specialty, India and emerging markets have continued to progress well,” Sun Pharma Managing Director Dilip Shanghvi well-known.

The specialty enterprise stays on a growth path and the company is devoted to proceed scaling it up, he added.

“Acquisition of Concert helps further strengthen our portfolio in dermatology. I believe deuruxolitinib can become a leading product to address highly unmet need in alopecia areata patients,” Shanghvi acknowledged.

Shares of the company had been shopping for and promoting 2.75 per cent up at Rs 970.65 apiece on the BSE.